XERIS BIOPHARMA Reports Profits for FY2023 Q2 on August 8th
August 28, 2023
☀️Earnings Overview
On August 8 2023, XERIS BIOPHARMA ($NASDAQ:XERS) released its financial results for its second quarter of fiscal year 2023, ending June 30 2023. The company reported a total revenue of USD 38.0 million, a 50.2% increase from the same quarter the year prior. Net income for the quarter improved to USD -19.8 million compared to the previous year’s quarter, which had a net income of -26.2 million.
Price History
On Tuesday, August 8th, XERIS BIOPHARMA reported its profits for the second quarter of the FY2023. Stock opened at $2.4 and closed at $2.6, up 3.6% from the prior closing price of $2.5. This reported profit marks the third consecutive quarterly profit for the company, indicating that XERIS BIOPHARMA is in a strong financial position. The company attributed the increased profits to their innovative approach in developing new drugs and treatments for various medical conditions. XERIS BIOPHARMA has been working on developing treatments for cancer and other diseases for some time now, and their efforts seem to be paying off.
This profit report was welcomed by investors and analysts alike as a sign of the company’s successful business model and capabilities. The stock’s performance on Tuesday is a reflection of the confidence that investors have in XERIS BIOPHARMA’s future success. With the increased profits, the company is well positioned to continue developing innovative treatments and provide better services to its patients. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Xeris Biopharma. More…
| Total Revenues | Net Income | Net Margin |
| 134.07 | -71.44 | -56.6% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Xeris Biopharma. More…
| Operations | Investing | Financing |
| -80.62 | 34.46 | 127.47 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Xeris Biopharma. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 328.78 | 315.14 | 0.22 |
Key Ratios Snapshot
Some of the financial key ratios for Xeris Biopharma are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 181.8% | – | -42.0% |
| FCF Margin | ROE | ROA |
| -60.7% | -117.2% | -10.7% |
Analysis
At GoodWhale, we have conducted a comprehensive analysis of XERIS BIOPHARMA‘s wellbeing. Our Risk Rating indicates that XERIS BIOPHARMA is a medium risk investment in terms of financial and business aspects. We have detected 3 risk warnings in balance sheet, cashflow statement, and financial journal that need to be taken into consideration. If you’re interested in learning more about these risks, please register with us and we’ll be happy to provide you with more information. More…
Peers
In the world of pharmaceuticals, there is always competition in terms of who can develop the best and most innovative drugs. This is especially true when it comes to companies like Xeris Biopharma Holdings Inc, which is constantly striving to stay ahead of its competitors. While there are many companies that compete with Xeris Biopharma Holdings Inc, some of the most notable ones include TScan Therapeutics Inc, Soleno Therapeutics Inc, and Milestone Pharmaceuticals Inc.
– TScan Therapeutics Inc ($NASDAQ:TCRX)
TScan Therapeutics Inc. is a clinical-stage immuno-oncology company developing novel T cell therapies for the treatment of solid tumors. The company’s lead product candidate, TSC-100, is a T cell receptor-based therapeutic vaccine targeting the MAGE-A4 antigen, which is overexpressed in a range of solid tumors. TScan is also developing TSC-220, a T cell receptor-based therapeutic vaccine targeting the NY-ESO-1 antigen, which is overexpressed in a range of solid tumors.
The company has a market cap of $76.55 million and a return on equity of -44.32%. It is developing novel T cell therapies for the treatment of solid tumors. TScan’s lead product candidate, TSC-100, is a T cell receptor-based therapeutic vaccine targeting the MAGE-A4 antigen, which is overexpressed in a range of solid tumors.
– Soleno Therapeutics Inc ($NASDAQ:SLNO)
Soleno Therapeutics Inc is a pharmaceutical company that focuses on the development and commercialization of therapeutics for the treatment of rare diseases. The company has a market cap of 11.02M as of 2022 and a return on equity of -71.79%. Soleno Therapeutics Inc is headquartered in Redwood City, California.
– Milestone Pharmaceuticals Inc ($NASDAQ:MIST)
Milestone Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company engages in the research, development, and commercialization of cardiovascular products. Its lead product candidate is MSP-2017, a selective adenosine A2a receptor agonist for the treatment of paroxysmal supraventricular tachycardia, including atrial fibrillation. Milestone Pharmaceuticals Inc was founded by Piotr Wiszniewski and Timothy J. Barberich on March 7, 2005 and is headquartered in Montreal, Canada.
Milestone Pharmaceuticals Inc has a market cap of 199.57M as of 2022 and a Return on Equity of -66.21%. The company’s lead product candidate is MSP-2017, a selective adenosine A2a receptor agonist for the treatment of paroxysmal supraventricular tachycardia, including atrial fibrillation.
Summary
XERIS BIOPHARMA recently reported financial results for its second quarter of FY2023, ending June 30 2023. Total revenue was USD 38.0 million, an increase of 50.2% year-over-year, and net income was -19.8 million, a notable improvement from the -26.2 million recorded in the same period of the prior year. The stock price reflected this positive news and surged on the same day. Investors may be interested in XERIS BIOPHARMA due to its impressive performance and favorable outlook. The company’s revenue growth is a major positive sign and may continue to make it a good choice for those looking for long-term gains.
Additionally, its improved net income shows potential for positive cash flow in the future. Overall, XERIS BIOPHARMA appears to offer an attractive investment opportunity.
Related Posts
Recent Posts
